- Home
- ESLA vs ABVC Comparison
ESLA vs ABVC Comparison
Compare ESLA & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | ABVC |
|---|---|---|
| Founded | 2021 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 30.9M |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ESLA | ABVC |
|---|---|---|
| Price | $0.48 | $1.17 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | 39.0K | ★ 126.7K |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.14 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $509,589.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $0.71 |
| 52 Week High | $3.15 | $3.39 |
Technical Indicators
Market Signals| Indicator | ESLA | ABVC |
|---|---|---|
| Relative Strength Index (RSI) | 23.83 | 56.38 |
| Support Level | N/A | $0.96 |
| Resistance Level | $0.85 | $1.14 |
| Average True Range (ATR) | 0.08 | 0.10 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 2.68 | 65.23 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.